

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Voluntary Announcement

Progress Regarding the Successful Development of a Dual-Platform Solution for Nipah Virus Detection by a Subsidiary and the Group's AI Healthcare Strategy Upgrade

I. BACKGROUND AND OPPORTUNITY

Recently, an outbreak of Nipah virus occurred in West Bengal, India. The World Health Organisation has classified it as a lethal zoonotic virus with a fatality rate ranging from 40% to 75%, for which no specific treatment or vaccine currently exists. Such emerging infectious disease outbreaks underscore the urgent global need for rapid, precise diagnostic and early warning capabilities within public health systems.

As a high-tech intellectual property capital operation platform with long-term expertise in life sciences, ETHK Labs Inc. (the “**Company**” or “**ETHK Labs**”) maintains close vigilance over global public health development. Leveraging its strategic deployment in pathogen molecular diagnostics and AI healthcare ecosystem, the Company continues to provide technological support for the prevention and control of emerging infectious diseases.

II. OFFICIAL LAUNCH OF ICXIVD'S DUAL-PLATFORM NIPAH VIRUS SOLUTION

Our subsidiary, Shenzhen ICXIVD Biotechnology Co., Ltd. (深圳碳華生物技術有限公司) (“**ICXIVD**”), was jointly established through strategic investment by ETHK Labs and iCarbonX, the biotech unicorn. Specialising in molecular diagnostics, it is a high-tech enterprise integrating R&D, production and technical services, dedicated to providing comprehensive one-stop molecular diagnostic solutions.

ICXIVD's core R&D team possesses years of extensive expertise in areas such as in vitro diagnostic reagent development, genomics, bioinformatics and artificial intelligence. Through efficient collaboration and innovative management, the company ensures its technical solutions combine forward-thinking vision with rapid translation capabilities.


The Company is pleased to announce that ICXIVD has successfully developed a dual-platform detection solution for Nipah virus. This solution provides comprehensive technical support spanning rapid screening to precise source tracing:

1. Intelligent Fluorescent PCR Rapid Detection Platform

Leveraging its proprietary AI primer design platform, ICXIVD deeply integrates intelligent modules including gene retrieval, automated primer design and multi-dimensional performance evaluation. Based on machine learning algorithms and an independently constructed species-specific nucleic acid database, the platform efficiently identifies and targets conserved gene regions of high-risk pathogens such as Nipah virus, enabling rapid and precise detection primer design and system optimisation.

This technological system ensures high specificity and sensitivity while significantly enhancing amplification uniformity and suppressing primer dimer formation, thereby strengthening the reliability of detection results. The “Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)” developed on such basis has the following characteristics:

- **Intelligent and simple operation:** Compatible with mainstream PCR instruments, supporting an integrated “sample-in, result-out” workflow that significantly reduces operational complexity and human error;
- **High-efficiency and precise detection:** Completes amplification testing within one hour, securing a critical window of time for pandemic emergency response;
- **System stability and compatibility:** Fully compatible with extraction systems (Guang Sheng Xie Bei No. 20240357), supporting flexible 48T/96T configurations to meet diverse throughput requirements.




ICXIVD Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)
Product Illustration

2. High-Throughput Sequencing and Intelligent Analysis Platform

ICXIVD has developed a localised pathogen sequencing solution based on second-generation sequencing technology, covering the entire workflow from “**wet lab experiments to dry analysis**”. Leveraging its proprietary, continuously updated multi-species pathogen genome database (encompassing 18,628 pathogens including bacteria, viruses, fungi and parasites), the system enables simultaneous detection and identification of Nipah virus alongside other co-existing pathogens.

Complemented by an in-house developed intelligent microbial data analysis and reporting platform, it integrates one-click bioinformatics analysis, automated report generation and visualisation capabilities. This enables a fully closed-loop workflow from sample reception to report issuance **within 17 hours**. The platform not only supports rapid identification of common, rare and emerging pathogens but also facilitates viral evolutionary tracking, transmission chain analysis and public health risk assessment, providing molecular evidence and data insights for precision prevention and control.



ICXIVD High-Throughput Sequencing and Intelligent Analysis Platform Solution

III. STRATEGIC ELEVATION: FROM “TESTING PRODUCTS” TO “INTELLIGENT MONITORING AS SERVICE”

The rapid deployment of Nipah virus detection capabilities not only demonstrates ICXIVD’s technological strengths but also represents a pivotal step in the pursuit of ETHK Labs’s broader AI healthcare strategy. With the steady progress of our acquisition of B-Soft Co., Ltd. (Stock code: 300451.SZ) where relevant procedures are advancing in an orderly manner, the Group is accelerating the establishment of a next-generation public health prevention and control paradigm centred on “AI Early Warning + Rapid Diagnosis + Ecosystem Synergy”.

1. **Ecosystem Synergy: Forging an Intelligent Surveillance Network**

With nearly three decades of expertise in healthcare informatisation, B-Soft has served nearly 7,000 medical institutions nationwide, amassing data asset covering over 300 million health records of residents and 100 million electronic medical records. Integrating its proprietary BsoftGPT medical large-model platform and AI-powered Critical Patient Precision Tracking System (APTS), ETHK Labs will be able to:

- Implement early syndrome monitoring and intelligent alerts for key regions and high-risk population;
- Enhance the timeliness and accuracy of emerging infectious disease detection and risk assessment through integrated data analysis;
- Establish a closed-loop “**monitoring-alert-diagnosis-intervention**” system, empowering disease control centres, customs authorities and medical institutions at all levels.

2. **Business Model Evolution: From Sales of Testing Kit to SaaS Service**

Moving forward, the Group will consolidate its existing diagnostic product portfolio while actively expanding service boundaries. We shall explore new models delivering “Intelligent Monitoring SaaS Platform” and “Data Insight Reporting Service” to governmental bodies, hospitals, customs authorities and other clients. This approach offers sustainability, replicability and scalability, enabling rapid adaptation to diverse infectious disease and chronic condition management scenarios. It facilitates a shift **from “passive response” to “proactive prevention and control”**.

3. **Aligning with National Strategies, Contributing to Societal Value**

The Company’s business strategy closely aligns with the national initiatives of “Healthy China 2030” and “AI Plus”, aiming to enhance the agility and resilience of public health systems through AI and big data technologies. The strengthening of early warning and precision diagnostic capabilities will mitigate the impact of major epidemics on healthcare systems, minimising disruption to economic and social operations. This reflects the corporate social responsibility of technology enterprises.

IV. FUTURE OUTLOOK: BUILDING A MORE AGILE PUBLIC HEALTH INTELLIGENCE DEFENCE SYSTEM ON THIS PREMISE

The rapid response to the Nipah virus outbreak represents a significant validation of ETHK Labs's integrated technological capabilities during public health emergencies. Building upon this foundation, we envision leveraging the refined **"AI Early Warning + Rapid Diagnosis + Ecosystem Collaboration"** capabilities honed through such incidents. The Group is committed to establishing an intelligent public health monitoring system that can be rapidly replicated and adapted to diverse scenarios involving emerging infectious diseases and chronic disease management.

This product launch and strategic articulation again reflects ETHK Labs's intensified implementation of the core paradigm of "intelligent capital enabling sustained knowledge-based profitability". We shall continue leveraging our three strategic curves, namely K1 (IVD distribution network), K2 (ETHK Labs ecosystem) and K3 (capital operations), to enhance innovation efficiency and commercial value within our ecosystem through technological convergence, data synergy and capital empowerment.

V. RISK DISCLOSURE

The Company hereby reminds investors that the development of Nipah virus outbreak remains uncertain, and the market demand for related diagnostic products is subject to multiple factors including epidemic fluctuations and policy direction. Furthermore, the acquisition of B-Soft has not yet been fully completed and the realisation of synergistic effects will require a certain period of time. Investors are advised to exercise due diligence when dealing in the shares of the Company.

By order of the Board
ETHK Labs Inc.
Lin Xianya
Executive Director

Hong Kong, 27 January 2026

As at the date of this announcement, the Board comprises two executive directors, namely, Mr. Lin Xianya and Mr. Chan Siu Kei Ken, two nonexecutive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent nonexecutive directors, namely, Dr. Zhong Renqian, Mr. Xu Da and Mr. Zhang Jianlei.

This announcement may contain certain forward-looking statements reflecting the Company's beliefs, plans or expectations regarding the future. These statements are based on a number of assumptions, current estimates and projections, and are subject to inherent risks, uncertainties or other factors that may or may not be beyond the Company's control. Actual results may differ. Nothing in these statements shall be construed as a warranty, representation or guarantee upon which reliance should be placed. Neither the Company nor any of its directors, employees, agents, advisers or representatives shall be under any obligation to update, supplement or correct these statements or to revise them to reflect future events.

In the event of any discrepancy between the Chinese and English versions of this notice, the Chinese version shall prevail.